Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 07 Oct 2018 Status changed from not yet recruiting to recruiting.
- 01 Oct 2018 Planned End Date changed from 10 Jan 2021 to 19 Mar 2021.
- 14 Aug 2018 New trial record